In a recent interview, McKesson Ventures Partner Michelle Snyder discussed the latest trends in digital health and how McKesson Ventures chooses its investments. As a corporate venture group, the McKesson Ventures team is well positioned to identify emerging trends in digital health and invest in innovative...
After being seen as an overly risky niche for years, women-focused digital health startups are finally beginning to see significant funding come their way. According to research and investment firm Rock Health, funding for women-focused digital health startups rose 105% last year to $418 million...
Accolade, which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, announced that it will release fiscal fourth quarter and full year 2021 financial results on Wednesday, May 5, 2021, after the market closes. In conjunction...
Komodo Health announced a $220 million Series E funding round led by Tiger Global Management and joined by Casdin Capital. Existing investors ICONIQ Growth, Andreesen Horowitz, and SVB Capital also participated in the round. The funding has propelled Komodo into the unicorn club with a...
Evidation Health today announced the close of a $153 million Series E growth funding round to rapidly expand its virtual health programs on Achievement, the largest digital health network in the United States. The round was co-led by OMERS Growth Equity and Kaiser Permanente Group...
Oncology data and informatics platform M2GEN has announced a significant investment by three major venture investment firms: Clayton, Dubilier & Rice (CD&R), Merck Global Health Innovation Fund (Merck GHI), and McKesson Ventures. The investment will recapitalize M2GEN to accelerate the growth of M2GEN’s clinicogenomic data...
GRAIL has announced that it is joining forces with AccessHope™ to offer a world-class service experience to people who use Galleri™, GRAIL’s first-of-kind multi-cancer early detection blood test. This collaboration is part of GRAIL’s effort to help patients and their healthcare providers achieve favorable outcomes...
The use of wearables has been of great benefit to clinical trials: researchers can gather far more data, more often, more objectively, and more easily than ever before. And over the past year, digital tools for remote measurement made it possible to continue trials that...
GRAIL today announced a partnership with the health system Providence to offer Galleri, GRAIL’s multi-cancer early detection blood test. Providence, based in Renton, Wash., will offer Galleri as a complement to recommended single cancer screening tests. Providence will initially deploy Galleri at its California, Washington, and...
GRAIL has entered an agreement with Quest Diagnostics to provide phlebotomy services in support of its multi-cancer early detection blood test. The test, called Galleri, is expected to go to market in the second quarter after its PATHFINDER multi-site interventional study. Under the agreement, Quest’s phlebotomy network,...